TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/3/24 16:06 | 5/1/24 | VCEL | Vericel Corp | MI | Health | BioPrd | Biological Products, (No Diag | McLaughlin Kevin F | MA | D | M.d | 0 | 0.00 | 0 | 3 | 37 | 12 | D | |||||||||||||||
4/28/23 16:04 | 4/27/23 | VCEL | Vericel Corp | MI | Health | BioPrd | Biological Products, (No Diag | McLaughlin Kevin F | MA | D | M.d | 0 | 0.00 | 0 | 3 | 43 | 9 | D | |||||||||||||||
4/29/22 16:10 | 4/27/22 | VCEL | Vericel Corp | MI | Health | BioPrd | Biological Products, (No Diag | McLaughlin Kevin F | MA | D | M.d | 0 | 0.00 | 0 | 3 | 74 | 6 | D | |||||||||||||||
9/24/21 19:36 | 9/23/21 | XLRN | Acceleron Pharma Inc | DE | Health | BioPrd | Biological Products, (No Diag | McLaughlin Kevin F | MA | O | SVP,CFO, | M.dm | 997 | 39.88 | 0 | 25 | 11 | D | |||||||||||||||
9/24/21 19:36 | 9/23/21 | XLRN | Acceleron Pharma Inc | DE | Health | BioPrd | Biological Products, (No Diag | McLaughlin Kevin F | MA | O | SVP,CFO, | S.dm | -4,008 | 160.33 | 0 | -25 | -70 | 11 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |